Recent Updates
Recently added Catalysts

AndroGel

Phase 3

Andropause | Small molecule | Other |Abbott Laboratories|Last Updated: Feb 21, 2019

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials1
Total Enrollment790
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00799617The Testosterone Trials in Older MenPHASE3 COMPLETED 790Nov 1, 2009Dec 1, 2018Feb 21, 201912 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Sexual Function Trial - Change in Psychosexual Daily Questionnaire Question 4 (PDQ-Q4) From Baseline to Month 12
1 year (change from baseline to month 3, 6, 9 and 12)

Baseline score and change in responses to Question 4 of the Psychosexual Daily Questionnaire (PDQ-Q4) from baseline to Month 12. Question 4 asks 12 questions about sexual activity. Scores on the PDQ-Q4 range from 0 to 12, with higher scores indicating more activity. The change is measured form the baseline value to Month 12.

Physical Function Trial - The 6-Minute Walk Test - no./Total no. (%)
1 year (Number of participants who increased walk distance > or = 50 meters, change from baseline to month 3, 6, 9 and 12)

The number and percentage of men who increased the distance walked in the 6-Minute Walk Test by at least 50 meters.

Vitality Trial - Increase in Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue Score Greater Than or Equal to 4 - no./Total no. (%)
1 year (Number of participants who increased FACIT-Fatigue score > or = to 4, change from baseline to month 3, 6, 9 and 12)

The number of participants whose score on the FACIT-Fatigue scale increased by at least 4 points. Scores on the FACIT- Fatigue scale range from 0 to 52, with higher scores indicating less fatigue.

Cardiovascular Trial - Assess Impact of Testosterone Treatment in Older Men on Noncalcified Plaque Volume
1 year (change in plaque volume measurement from baseline to month 12)

Non-calcified coronary artery plaque volume, mm3, as determined by coronary computed tomographic angiography (CTA), mean difference in change from baseline to month 12

Bone Trial - Volumetric Bone Mineral Density (BMD) of Spine Trabecular Bone by Quantitative Computed Tomography (QCT) in Older Men With Low Testosterone
1 year (QCT measurement of BMD change between baseline and month 12)

Volumetric Bone Mineral Density (BMD) of spine trabecular bone as measured by QCT, mg/cm3, the calculated change in measurement from baseline to Month 12

Cognitive Function Trial - Delayed Paragraph Recall Wechsler Memory Scale Revised Logical Memory II (WMS-R LMII)
1 year (change from baseline to month 6 and month 12)

Baseline score and change in score of the Wechsler Memory Scale Revised Logical Memory II (WMS-R LMII) test of Delayed Paragraph Recall, at baseline, Month 6 and Month 12. The WMS-R LM II involves a delayed paragraph recall activity scored in two components, each ranging from 0-25. The final score is the sum of each component, therefore falling in the range 0-50. WMS-R LM II scores were treated as continuous with change compared between treatment arms using linear random effects models adjusting for several factors: site, indicator variables of participation in each primary efficacy trial, baseline testosterone concentration (\<200), age (≤ 75), use of anti-depressants, use of PDE-inhibitors, baseline WMSR, categorical education, and version of the WMSR.

Anemia Trial - Effect of Testosterone on Hemoglobin Levels - Unexplained Anemia
1 year (change in hemoglobin g/dL from baseline to month 3, 6, 9 and 12)

Proportion of men age 65 years or older with unexplained anemia who increased their hemoglobin level by 1.0 g/dL from baseline. Values are No. (%) for dichotomous outcomes. Dichotomous hemoglobin response is an increase of 1 g/dL or more from baseline.

Secondary Endpoints
Sexual Function Trial - Sexual Desire Domain
1 year (change from baseline to month 3, 6, 9 and 12)
Sexual Function Trial - Erectile Function
1 year (change from baseline to month 3, 6, 9 and 12)
Physical Function Trial - 6 Minute Walk Test - Total Walking Distance in Meters
1 year (change from baseline to month 3, 6, 9 and 12)
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
AndroGel® (testosterone gel)ACTIVE_COMPARATORThe initial dose of AndroGel will be 5.0 g (containing 50 mg of testosterone) once a day. Participants will apply AndroGel once daily to the shoulders, abdomen or upper arms. The serum testosterone concentration will be measured monthly for the first three months, then at months 6, 9 and 12. If the testosterone concentration is not between 500 and 800 ng/dL at any time point, the dose will be either increased by increments of 1.25-2.5 g/day, up to a maximum of 15 g/day or decreased by increments of 1.25-3.75 ng/day. Participants will be taught how to apply the gel and they will be provided with written instructions and precautions. This information will be reviewed at each contact and visit.
Placebo gelPLACEBO_COMPARATORPlacebo gel is identical to the testosterone gel and is supplied in an identical pump bottle container. It is applied to the shoulders, abdomen or upper arms once a day. Participants will be taught how to apply the gel and they will be provided with written instructions and precautions. This information will be reviewed at each contact and visit.
Interventions
NameTypeDescription
AndroGel® (testosterone gel)DRUGTestosterone levels will be measured at regular intervals in order to achieve a testosterone level in the desired range.
PlaceboDRUGTestosterone levels will be measured at regular intervals.
Unlock Study Design Details
Eligibility Criteria
Age Range65 Years — N/A
SexMALE
Healthy VolunteersYes
Study Sites12

Inclusion Criteria: * Men greater than or equal to 65 years old * Total serum testosterone concentration \< 275 and \< 300 ng/dL at 7 -10 AM at each of two screening visits Exclusion Criteria: * Diagnosed prostate cancer, prostatic intraepithelial neoplasia (PIN), prostate nodule or, by the Prost...

Countries:United States
Unlock Eligibility Criteria